An observational study in HIV Prevention, sponsored by DatAids. Recruiting at 31 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.
Sponsored by DatAids · Observational
DatAIDS prevention is a cohort study of HIV prevention in over 23 HIV sites in France including overseas, aiming to describe HIV prevention in every aspect including HIV screening, STI and hepatitis screening, post-exposure prophylaxis and pre-exposure prophylaxis
DatAids is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All persons attending for HIV prevention and seeking care at 23 centers using NADIS are included in the Dataids Prevention cohort after receiving oral information and giving written consent. NADIS is an electronic medical record (EMR) for HIV infection (and Hepatitis B virus (HBV), Hepatitis C virus (HCV), STI) and HIV prevention in French public hospitals.
The Dataids Prevention study recruits persons HIV- and above the age of 18 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Number of patients enrolled for HIV prevention in the cohort
Demographics, risk factors clinical and biological characteristics, treatment of patients enrolled for HIV prevention in the cohort
Time frame: From date of enrollment, through study completion, an average of 1 year
Proportion of persons enrolled for pre-exposure prophylaxis in the cohort
Demographics, risk factors clinical and biological characteristics, treatment of patients attending for pre-exposure prophylaxis in the cohort
Time frame: From date of enrollment, through study completion, an average of 1 year
Proportion of persons enrolled for post-exposure prophylaxis in the cohort
Demographics, risk factors clinical and biological characteristics, treatment of patients attending for post-exposure prophylaxis in the cohort
Time frame: From date of enrollment, through study completion, an average of 1 year
Proportion of persons enrolled for hepatitis screening in the cohort
Demographics, risk factors clinical and biological characteristics, treatment of patients attending for hepatitis screening in the cohort
Time frame: From date of enrollment, through study completion, an average of 1 year
Proportion of persons enrolled for pre-exposure prophylaxis in the cohort according to national French guidelines
Adequation between prevention practices and guidelines
Time frame: From date of enrollment, through study completion, an average of 1 year
Proportion of persons enrolled for post-exposure prophylaxis in the cohort according to national French guidelines
Adequation between prevention practices and guidelines
Time frame: From date of enrollment, through study completion, an average of 1 year
Incidence of STIs
Time frame: From date of enrollment, through study completion, an average of 1 year
Incidence of hepatitis
Time frame: From date of enrollment, through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2019 (actual). Primary completion is estimated for Jan 2030, 132 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
DatAids